Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Viral Infection in the Intensive Care Unit before, during, and...
share announcement

Viral Infection in the Intensive Care Unit before, during, and after COVID-19

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Intensive Care".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 1371

Special Issue Editors

Dr. Marco Goeijenbier

E-Mail Website
Guest Editor
1. Department of Intensive Care, Erasmus MC, Rotterdam, The Netherlands
Department of Intensive Care, Spaarne Gasthuis, Hoofddorp, The Netherlands
Interests: intensive care; respiratory medicine; virology; infectious disaeses; tropical medicine; immune modulation; coagulation
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Henrik Endeman

E-Mail Website
Guest Editor
Department of Intensive Care Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Interests: intensive care; respiratory medicine; virology; infectious disaeses; tropical medicine; immune modulation; coagulation

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue of the Journal of Clinical Medicine focusing on the management of virus infection in the intensive care setting, specifically addressing the emerging field of viro-sepsis. In light of the profound impact of the COVID-19 pandemic on critical care medicine, we are particularly interested in articles that compare knowledge and practices before and after the pandemic. Additionally, we welcome submissions on novel treatments, groundbreaking insights, expert opinions, guidelines, and the potential role of antiviral therapies.

The Journal of Clinical Medicine is dedicated to advancing the understanding and practice of medicine, with a specific emphasis on clinical research and evidence-based approaches. As the scientific community continues to grapple with the challenges posed by viral infections in the intensive care unit, this Special Issue provides a unique opportunity to consolidate and disseminate the latest advancements and perspectives in the field.

We invite clinicians, researchers, and scholars to submit their original research papers, and reviews to contribute to this Special Issue. Potential topics of interest include, but are not limited to:

  1. Comparative studies on the management of virus infection in the intensive care unit before and after the COVID-19 pandemic.
  2. Novel treatments and therapeutic approaches for viro-sepsis.
  3. Insights into the pathophysiology and immunology of viro-sepsis.
  4. Expert opinions and perspectives on the challenges and opportunities in viro-sepsis management.
  5. Guidelines and best practices for the management of viro-sepsis in critical care settings.
  6. The potential role of antiviral therapies in the treatment of viro-sepsis.

Authors are encouraged to present evidence-based research, rigorous methodologies, and clear clinical implications. Manuscripts should adhere to the guidelines provided by the Journal of Clinical Medicine, which can be found on the journal's website.

We believe that this Special Issue will foster meaningful discussion, exchange of ideas, and contribute to the advancement of clinical practice in the management of viro-sepsis. We look forward to your contributions and collaboration in this important endeavor.

Dr. Marco Goeijenbier
Prof. Dr. Henrik Endeman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • virus infections
  • viro-sepsis
  • COVID-19
  • intensive care
  • respiratory medicine
  • personalized medicine
  • critical care
  • coagulopathy
  • anti-viral therapy in intensive care
  • immune modulation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 246 KiB  
Article
A Transcriptomic Severity Classifier IMX-SEV-3b to Predict Mortality in Intensive Care Unit Patients with COVID-19: A Prospective Observational Pilot Study
by Katrijn Daenen, Kirby Tong-Minh, Oliver Liesenfeld, Sara C. M. Stoof, Jilske A. Huijben, Virgil A. S. H. Dalm, Diederik Gommers, Eric C. M. van Gorp and Henrik Endeman
J. Clin. Med. 2023, 12(19), 6197; https://doi.org/10.3390/jcm12196197 - 26 Sep 2023
Viewed by 1122
Abstract
The prediction of disease outcomes in COVID-19 patients in the ICU is of critical importance, and the examination of host gene expressions is a promising tool. The 29-host mRNA Inflam-matix-Severity-3b (IMX-SEV-3b) classifier has been reported to predict mortality in emergency department COVID-19 patients [...] Read more.
The prediction of disease outcomes in COVID-19 patients in the ICU is of critical importance, and the examination of host gene expressions is a promising tool. The 29-host mRNA Inflam-matix-Severity-3b (IMX-SEV-3b) classifier has been reported to predict mortality in emergency department COVID-19 patients and surgical ICU patients. The accuracy of the IMX-SEV-3b in predicting mortality in COVID-19 patients admitted to the ICU is yet unknown. Our aim was to investigate the accuracy of the IMX-SEV-3b in predicting the ICU mortality of COVID-19 patients. In addition, we assessed the predictive performance of routinely measured biomarkers and the Sequential Organ Failure Assessment (SOFA) score as well. This was a prospective observational study enrolling COVID-19 patients who received mechanical ventilation on the ICU of the Erasmus MC, the Netherlands. The IMX-SEV-3b scores were generated by amplifying 29 host response genes from blood collected in PAXgene® Blood RNA tubes. A severity score was provided, ranging from 0 to 1 for increasing disease severity. The primary outcome was the accuracy of the IMX-SEV-3b in predicting ICU mortality, and we calculated the AUROC of the IMX-SEV-3b score, the biomarkers C-reactive protein (CRP), D-dimer, ferritin, leukocyte count, interleukin-6 (IL-6), lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), procalcitonin (PCT) and the SOFA score. A total of 53 patients were included between 1 March and 30 April 2020, with 47 of them being included within 72 h of their admission to the ICU. Of these, 18 (34%) patients died during their ICU stay, and the IMX-SEV-3b scores were significantly higher in non-survivors compared to survivors (0.65 versus 0.57, p = 0.05). The Area Under the Receiver Operating Characteristic Curve (AUROC) for prediction of ICU mortality by the IMX-SEV-3b was 0.65 (0.48–0.82). The AUROCs of the biomarkers ranged from 0.52 to 0.66, and the SOFA score had an AUROC of 0.81 (0.69–0.93). The AUROC of the pooled biomarkers CRP, D-dimer, ferritin, leukocyte count, IL-6, LDH, NLR and PCT for prediction of ICU mortality was 0.81 (IQR 0.69–0.93). Further validation in a larger interventional trial of a point-of-care version of the IMX-SEV-3b classifier is warranted to determine its value for patient management. Full article
(This article belongs to the Special Issue Viral Infection in the Intensive Care Unit before, during, and after COVID-19)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop